{
    "clinical_study": {
        "@rank": "151392", 
        "acronym": "CIMI", 
        "arm_group": {
            "arm_group_label": "Imiglucerase", 
            "arm_group_type": "Experimental", 
            "description": "Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.\nSecondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
        }, 
        "brief_summary": {
            "textblock": "Rational: Imiglucerase has been used to treat Gaucher disease since 1997 but data about its\n      pharmacokinetics have been partial; investigators know that imiglucerase undergoes a quick\n      clearance from plasma compartment following the infusion (1/2 life: 1-6 min, from tissue:\n      <24h), an observation apparently contradictory with usual infusion rhythm (one infusion\n      every two weeks). Furthermore, by going by GD response, the rhythm of Infusion is sometimes\n      diminished (for example, every 3 or 4 wks) without pharmacological rational ; In parallel,\n      investigators demonstrated that monocytes represent a satisfactory surrogate of GD target\n      cells and that enzyme activity into monocytes varies between individuals.\n\n      Our hypothesis is that enzyme activity into monocyte compartment could be different and\n      could be related to GD response.\n\n      Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target\n      cellular compartment depending on dose and frequency of infusions.\n\n      Secondary purposes : 1) to establish a possible relationship between the intra-monocytic\n      activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease\n      and to define a possible threshold value of enzyme activity; 2) to establish a better\n      correlation with known biomarkers of disease (routine markers and markers recently\n      identified), which would better predict and / or monitor response to treatment ; 3) to\n      compare the residual and natural rate of activity enzyme intra-monocytic for untreated\n      patients (low severity disease)."
        }, 
        "brief_title": "Intra-monocyte Imiglucerase Kinetics in Gaucher Disease", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gaucher Disease", 
        "condition_browse": {
            "mesh_term": "Gaucher Disease"
        }, 
        "detailed_description": {
            "textblock": "Rational: Imiglucerase has been used to treat Gaucher disease since 1997 but data about its\n      pharmacokinetics have been partial; investigators know that imiglucerase undergoes a quick\n      clearance from plasma compartment following the infusion (1/2 life: 1-6 min, from tissue:\n      <24h), an observation apparently contradictory with usual infusion rhythm (one infusion\n      every two weeks). Furthermore, by going by GD response, the rhythm of Infusion is sometimes\n      diminished (for example, every 3 or 4 wks) without pharmacological rational ; In parallel,\n      investigators demonstrated that monocytes represent a satisfactory surrogate of GD target\n      cells and that enzyme activity into monocytes varies between individuals. Our hypothesis is\n      that enzyme activity into monocyte compartment could be different and could be related to GD\n      response.\n\n      Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target\n      cellular compartment depending on dose and frequency of infusions.\n\n      Secondary purposes : 1) to establish a possible relationship between the intra-monocytic\n      activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease\n      and to define a possible threshold value of enzyme activity; 2) to establish a better\n      correlation with known biomarkers of disease (routine markers and markers recently\n      identified), which would better predict and / or monitor response to treatment ; 3) to\n      compare the residual and natural rate of activity enzyme intra-monocytic for untreated\n      patients (low severity disease)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient older than 12 years old with Gaucher disease type 1 or type 3 and having\n             signed an informed consent\n\n          -  Treated with imiglucerase (Cerezyme \u00ae) with a stable therapeutic strategy for at\n             least 3 months.\n\n        OR\n\n          -  Untreated patient, with no therapeutic indication at the time of inclusion and having\n             a diagnosis older than 2 years (non progressive disease)\n\n          -  Patients must have a social security system\n\n        Exclusion Criteria:\n\n          -  Age <12 years old\n\n          -  Gaucher disease unproven\n\n          -  Gaucher disease treated with therapeutic changes in the previous 3 months, or current\n             treatment different from imiglucerase\n\n          -  Gaucher disease untreated whose diagnosis was established for under  2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951989", 
            "org_study_id": "CHU-0167", 
            "secondary_id": "2012-019622-13"
        }, 
        "intervention": {
            "arm_group_label": "Imiglucerase", 
            "intervention_name": "Imigluc\u00e9rase (drug) pharmacokinetics", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gaucher disease", 
            "Imiglucerase", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "email": "placarin@chu-clermontferrand.fr", 
                "last_name": "Patrick LACARIN", 
                "phone": "04 73 75 11 95"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont-Ferrand", 
                    "country": "France", 
                    "zip": "63003"
                }, 
                "name": "CHU Clermont-Ferrand"
            }, 
            "investigator": [
                {
                    "last_name": "Marc BERGER", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Nadia BELMATOUG", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Agathe MASSEAU", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christine SERRATRICE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christian ROSE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Vassili VALAYANNOPOULOS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Thierry BILLETTE DE VILLEMEUR", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Olivier LIDOVE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christian LAVIGNE", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pierre KAMINSKY", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yves-Marie PERS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Catherine CAILLAUD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Intra-monocytic Imiglucerase Kinetic and Its Correlation With Clinical and Biological Gaucher Disease", 
        "overall_contact": {
            "email": "placarin@chu-clermontferrand.fr", 
            "last_name": "Patrick LACARIN", 
            "phone": "04 73 75 11 95"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Clermont-Ferrand", 
            "last_name": "Marc BERGER", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Enzyme intra-monocyte activity (sum of endogenous enzyme activities and therapeutic enzyme) in patients treated with imiglucerase will be assessed at different times between infusions (8 to 10 time points), and just before an infusion (residual rate). The population pharmacokinetics method allows to perform this analysis in measurement windows that are not necessarily included in the period between two consecutive infusions of imiglucerase but may be spread over several cycles.", 
            "measure": "Enzyme intra-monocyte activity (sum of endogenous enzyme activities and therapeutic enzyme)in patients treated with imiglucerase", 
            "safety_issue": "No", 
            "time_frame": "at day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951989"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetics descriptive criteria are the area under curve at balance, the terminal half-life and the residual rate.", 
                "measure": "Residual rate", 
                "safety_issue": "No", 
                "time_frame": "every 6 months during 2 years."
            }, 
            {
                "measure": "Endogeneous intra-monocyte glucoc\u00e9r\u00e9brosidase activity from untreated patients", 
                "safety_issue": "No", 
                "time_frame": "every 6 months during 2 years"
            }, 
            {
                "description": "1) routine biomarkers (ACE, TRAP, chitotriosidase, ferritin) and 2) potentially interesting biomarkers but not routinely evaluated in France (CCL18, MIP1a, MIP1b, MCP1, IL-8, glycated ferritin).\n- Gaucher disease status will be assessed by clinical and biological criteria defined by the HAS (Haute Autorit\u00e9 de Sant\u00e9 = High Health Authority). We will consider the two-year periods before and after treatment to identify progressive diseases (clinical or biological significant events associated with Gaucher disease in the two years before and 2 years after the enrolment time", 
                "measure": "Biomarker dosages will provide serum concentration values", 
                "safety_issue": "No", 
                "time_frame": "at D0, M3, M6 and every 6 months during 2 years:"
            }
        ], 
        "source": "University Hospital, Clermont-Ferrand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Clermont-Ferrand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}